Skip to content
1887

Microbial Genomics logo Microbial Genomics

Volume 11, Issue 3

Investigating two decades of bacteraemia in the Gelderland area, the Netherlands, using whole-genome sequencing Open Access

Abstract

In the Netherlands, the 7-valent pneumococcal conjugate vaccine (PCV) was introduced to the childhood immunization programme in 2006 and replaced by the 10-valent PCV (PCV10, GSK) in 2011. To describe invasive pneumococcal disease in the era of childhood PCV vaccination on pneumococcal bacteraemia across all ages, we collected and sequenced 979 pneumococcal blood isolates from consecutive patients with pneumococcal bacteraemia in the Gelderland area, the Netherlands, between 2000 and 2020. In total, 58% of the bacteraemia cases (=563/979) occurred in the elderly population. Compared to the pre-PCV period (2000–2005), the odds ratio for non-PCV10 bacteraemia was 17.5 (CI 9.9–31.6; <0.001) in the late-PCV10 period, showing an overall increase in the proportion of bacteraemia cases being caused by non-vaccine serotype pneumococci (2016–2020). The increase in non-PCV10 serotypes is mainly driven by an expansion of lineage global pneumococcal sequencing cluster 3 (GPSC3) expressing serotype 8, alongside the emergence of serotype 12F that was mediated by multiple lineages (GPSC32/GPSC26/GPSC55). Both serotypes 8 and 12F were included in the latest PCV20 formulation that is licensed to be used in children and adults in Europe. Over 20 years, we observed a low prevalence of antimicrobial resistance (AMR) as predicted by genome data. There were no significant changes in AMR prevalence after vaccine introduction (>0.05 for all comparisons). We saw a stably low prevalence of reduced penicillin susceptibility, which was observed in multiple pneumococcal lineages, with GPSC10 being the most common in the Gelderland collection, whilst GPSC1 and GPSC6 were common among the penicillin-resistant pneumococcal blood culture isolates provided by the Netherlands Reference Laboratory for Bacterial Meningitis. Comparison to global collections of GPSC10, GPSC1 and GPSC6 isolates favored the likelihood of separate introductions of penicillin-resistant isolates rather than cloncal expansion. Genomic surveillance of pneumococcal bacteraemia in this unbiased population sample in the Netherlands supports the use of higher valency PCVs, such as PCV20, especially in adults, to prevent future bacteraemia cases caused by in the Gelderland area, the Netherlands, while maintaining a low prevalence of AMR in the pneumococcal population.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): serotype , antimicrobial resistance , invasive pneumococcal disease (IPD) , pneumococcal conjugate vaccine (PCV) , pneumococcal lineage and the Netherlands
Funding
This study was supported by the:
  • Bill and Melinda Gates Foundation (Award OPP1189062)
    • Principal Award Recipient: NotApplicable
  • Wellcome Trust (Award 206196)
    • Principal Award Recipient: NotApplicable
© 2025 The Authors
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License.
Loading

Article metrics loading...

/content/journal/mgen/10.1099/mgen.0.001377
2025-03-18
2026-02-17

Metrics

Loading full text...

Full text loading...

/deliver/fulltext/mgen/11/3/mgen001377.html?itemId=/content/journal/mgen/10.1099/mgen.0.001377&mimeType=html&fmt=ahah

References

  1. Henriques-Normark B, Tuomanen EI. The pneumococcus: epidemiology, microbiology, and pathogenesis. Cold Spring Harb Perspect Med 2013; 3:a010215 [View Article] [PubMed]
     [Google Scholar]
  2. Hanquet G, Krizova P, Valentiner-Branth P, Ladhani SN, Nuorti JP et al. Effect of childhood pneumococcal conjugate vaccination on invasive disease in older adults of 10 European countries: implications for adult vaccination. Thorax 2019; 74:473–482 [View Article] [PubMed]
     [Google Scholar]
  3. Ciruela P, Izquierdo C, Broner S, Muñoz-Almagro C, Hernández S et al. The changing epidemiology of invasive pneumococcal disease after PCV13 vaccination in a country with intermediate vaccination coverage. Vaccine 2018; 36:7744–7752 [View Article] [PubMed]
     [Google Scholar]
  4. Lo SW, Gladstone RA, van Tonder AJ, Lees JA, Du Plessis M et al. Pneumococcal lineages associated with serotype replacement and antibiotic resistance in childhood invasive pneumococcal disease in the post-PCV13 era: an international whole-genome sequencing study. Lancet Infect Dis 2019; 19:759–769 [View Article] [PubMed]
     [Google Scholar]
  5. Agudelo CI, Castañeda-Orjuela C, Brandileone MC de C, Echániz-Aviles G, Almeida SCG et al. The direct effect of pneumococcal conjugate vaccines on invasive pneumococcal disease in children in the latin american and caribbean region (SIREVA 2006-17): a multicentre, retrospective observational study. Lancet Infect Dis 2021; 21:405–417 [View Article] [PubMed]
     [Google Scholar]
  6. Balsells E, Guillot L, Nair H, Kyaw MH. Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: a systematic review and meta-analysis. PLoS One 2017; 12:e0177113 [View Article] [PubMed]
     [Google Scholar]
  7. Savulescu C, Krizova P, Lepoutre A, Mereckiene J, Vestrheim DF et al. Effect of high-valency pneumococcal conjugate vaccines on invasive pneumococcal disease in children in SpIDnet countries: an observational multicentre study. Lancet Respir Med 2017; 5:648–656 [View Article] [PubMed]
     [Google Scholar]
  8. Almeida SCG, Lo SW, Hawkins PA, Gladstone RA, Cassiolato AP et al. Genomic surveillance of invasive Streptococcus pneumoniae isolates in the period pre-PCV10 and post-PCV10 introduction in Brazil. Microb Genom 2021; 7:000635 [View Article] [PubMed]
     [Google Scholar]
  9. Desmet S, Theeten H, Laenen L, Cuypers L, Maes P et al. Characterization of emerging serotype 19A pneumococcal strains in invasive disease and carriage, Belgium. Emerg Infect Dis 2022; 28:1606–1614 [View Article] [PubMed]
     [Google Scholar]
  10. Hammitt LL, Etyang AO, Morpeth SC, Ojal J, Mutuku A et al. Effect of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a longitudinal surveillance study. Lancet 2019; 393:2146–2154 [View Article] [PubMed]
     [Google Scholar]
  11. Ladhani SN, Collins S, Djennad A, Sheppard CL, Borrow R et al. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000–17: a prospective national observational cohort study. Lancet Infect Dis 2018; 18:441–451 [View Article] [PubMed]
     [Google Scholar]
  12. Kavalari ID, Fuursted K, Krogfelt KA, Slotved H-C. Molecular characterization and epidemiology of Streptococcus pneumoniae serotype 24F in Denmark. Sci Rep 2019; 9:5481 [View Article] [PubMed]
     [Google Scholar]
  13. Lo SW, Mellor K, Cohen R, Alonso AR, Belman S et al. Emergence of a multidrug-resistant and virulent Streptococcus pneumoniae lineage mediates serotype replacement after PCV13: an international whole-genome sequencing study. Lancet Microbe 2022; 3:e735–e743 [View Article] [PubMed]
     [Google Scholar]
  14. von Gottberg A, Kleynhans J, de Gouveia L, Tempia S, Meiring S et al. Long-term effect of pneumococcal conjugate vaccines on invasive pneumococcal disease incidence among people of all ages from national, active, laboratory-based surveillance in South Africa, 2005–19: a cohort observational study. Lancet Glob Health 2024; 12:e1470–e1484 [View Article]
     [Google Scholar]
  15. Ndlangisa KM, du Plessis M, Lo S, de Gouveia L, Chaguza C et al. A Streptococcus pneumoniae lineage usually associated with pneumococcal conjugate vaccine (PCV) serotypes is the most common cause of serotype 35B invasive disease in South Africa, following routine use of PCV. Microb Genom 2022; 8:000746 [View Article] [PubMed]
     [Google Scholar]
  16. Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis 2015; 15:301–309 [View Article] [PubMed]
     [Google Scholar]
  17. Gagetti P, Lo SW, Hawkins PA, Gladstone RA, Regueira M et al. Population genetic structure, serotype distribution and antibiotic resistance of Streptococcus pneumoniae causing invasive disease in children in Argentina. Microb Genom 2021; 7:000636 [View Article] [PubMed]
     [Google Scholar]
  18. Bertran M, D’Aeth JC, Abdullahi F, Eletu S, Andrews NJ et al. Invasive pneumococcal disease 3 years after introduction of a reduced 1 + 1 infant 13-valent pneumococcal conjugate vaccine immunisation schedule in England: a prospective national observational surveillance study. Lancet Infect Dis 2024; 24:546–556 [View Article] [PubMed]
     [Google Scholar]
  19. Stanley S, Silva-Costa C, Gomes-Silva J, Melo-Cristino J, Malley R et al. CC180 clade dynamics do not universally explain Streptococcus pneumoniae serotype 3 persistence post-vaccine: a global comparative population genomics study. Infect Dis 20242024.08.29.24312665 [View Article] [PubMed]
     [Google Scholar]
  20. Rodenburg GD, de Greeff SC, Jansen AGCS, de Melker HE, Schouls LM et al. Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands. Emerg Infect Dis 2010; 16:816–823 [View Article] [PubMed]
     [Google Scholar]
  21. Knol MJ, Wagenvoort GHJ, Sanders EAM, Elberse K, Vlaminckx BJ et al. Invasive pneumococcal disease 3 years after introduction of 10-valent pneumococcal conjugate vaccine, the Netherlands. Emerg Infect Dis 2015; 21:2040–2044 [View Article] [PubMed]
     [Google Scholar]
  22. World Health Organization Pneumococcal vaccination coverage; 2023 https://immunizationdata.who.int/pages/coverage/pcv.html?CODE=NLD&ANTIGEN=&YEAR= accessed 4 July 2023
  23. Vestjens SMT, Sanders EAM, Vlaminckx BJ, de Melker HE, van der Ende A et al. Twelve years of pneumococcal conjugate vaccination in the Netherlands: impact on incidence and clinical outcomes of invasive pneumococcal disease. Vaccine 2019; 37:6558–6565 [View Article] [PubMed]
     [Google Scholar]
  24. Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet 2011; 378:1962–1973 [View Article] [PubMed]
     [Google Scholar]
  25. Koelman DLH, van Kassel MN, Bijlsma MW, Brouwer MC, van de Beek D et al. Changing epidemiology of bacterial meningitis since introduction of conjugate vaccines: 3 decades of national meningitis surveillance in the Netherlands. Clin Infect Dis 2021; 73:e1099–e1107 [View Article] [PubMed]
     [Google Scholar]
  26. van Daalen FV, Boersma WG, van de Garde EMW, van der Mooren FM, Roescher N. Management of Community-Acquired Pneumonia in Adults: the 2024 Practice Guideline from The Dutch Working Party on Antibiotic Policy (SWAB) and Dutch Association of Chest Physicians (NVALT); 2024 https://swab.nl/en/exec/file/download/300
  27. Gelderland-Zuid Swing Viewer; 2024 https://gezondheidincijfers.ggdgelderlandzuid.nl/viewer?cat_open_code=cgdicwmll1vib accessed 9 September 2024
  28. Lees JA, Harris SR, Tonkin-Hill G, Gladstone RA, Lo SW et al. Fast and flexible bacterial genomic epidemiology with PopPUNK. Genome Res 2019; 29:304–316 [View Article] [PubMed]
     [Google Scholar]
  29. Epping L, van Tonder AJ, Gladstone RA, The Global Pneumococcal Sequencing Consortium, Bentley SD et al. SeroBA: rapid high-throughput serotyping of Streptococcus pneumoniae from whole genome sequence data. Microb Genom 2018; 4:e000186 [View Article] [PubMed]
     [Google Scholar]
  30. Seemann T. Mlst: id: scan contig files against pubmlst typing schemes Github [accessed July 2023] 2023 https://github.com/tseemann/mlst
     [Google Scholar]
  31. PubMLST Public databases for molecular typing and microbial genome diversity; 2023 https://pubmlst.org/ accessed 4 July 2023
  32. Gladstone RA, Lo SW, Lees JA, Croucher NJ, van Tonder AJ et al. International genomic definition of pneumococcal lineages, to contextualise disease, antibiotic resistance and vaccine impact. EBioMedicine 2019; 43:338–346 [View Article] [PubMed]
     [Google Scholar]
  33. Metcalf BJ. Sanger_SPN_Scripts-Ref. Github 2017 https://github.com/BenJamesMetcalf/Sanger_SPN_Scripts-Ref accessed 4 July 2023
     [Google Scholar]
  34. Metcalf BJ, Chochua S, Gertz RE Jr, Li Z, Walker H et al. Using whole genome sequencing to identify resistance determinants and predict antimicrobial resistance phenotypes for year 2015 invasive pneumococcal disease isolates recovered in the United States. Clin Microbiol Infect 2016; 22:1002 [View Article] [PubMed]
     [Google Scholar]
  35. CLSI Performance Standards for Antimicrobial Susceptibility Testing: CLSI Supplement M100, 28th edn. Wayne, PA: Clinical and Laboratory Standards Institute;
  36. Page AJ, Taylor B, Delaney AJ, Soares J, Seemann T et al. SNP-sites: rapid efficient extraction of SNPs from multi-FASTA alignments. Microb Genom 2016; 2:e000056 [View Article] [PubMed]
     [Google Scholar]
  37. Price MN, Dehal PS, Arkin AP. FastTree 2--approximately maximum-likelihood trees for large alignments. PLoS One 2010; 5:e9490 [View Article] [PubMed]
     [Google Scholar]
  38. Monocle data viewer GPS project; 2023 https://data.monocle.sanger.ac.uk/ accessed 5 July 2023
  39. Derelle R, von Wachsmann J, Mäklin T, Hellewell J, Russell T et al. Seamless, rapid, and accurate analyses of outbreak genomic data using split k-mer analysis. Genome Res 2024; 34:1661–1673 [View Article] [PubMed]
     [Google Scholar]
  40. Croucher NJ, Page AJ, Connor TR, Delaney AJ, Keane JA et al. Rapid phylogenetic analysis of large samples of recombinant bacterial whole genome sequences using Gubbins. Nucleic Acids Res 2015; 43:e15 [View Article] [PubMed]
     [Google Scholar]
  41. Netherlands Reference Laboratory for Bacterial Meningitis (AMC/RIVM) Bacterial meningitis in the Netherlands; annual report 2021. Amsterdam: University of Amsterdam; 2022
  42. Dixon P. VEGAN, a package of R functions for community ecology. J Veg Sci 2003; 14:927–930 [View Article]
     [Google Scholar]
  43. Vissers M, Wijmenga-Monsuur AJ, Knol MJ, Badoux P, van Houten MA et al. Increased carriage of non-vaccine serotypes with low invasive disease potential four years after switching to the 10-valent pneumococcal conjugate vaccine in the Netherlands. PLoS One 2018; 13:e0194823 [View Article] [PubMed]
     [Google Scholar]
  44. Hansen CB, Fuursted K, Valentiner-Branth P, Dalby T, Jørgensen CS et al. Molecular characterization and epidemiology of Streptococcus pneumoniae serotype 8 in Denmark. BMC Infect Dis 2021; 21:421 [View Article] [PubMed]
     [Google Scholar]
  45. Silva-Costa C, Gomes-Silva J, Teodoro I, Ramirez M, Melo-Cristino J et al. Invasive pneumococcal disease in adults in Portugal: the importance of serotypes 8 and 3 (2015-2018). Microorganisms 2021; 9:1016 [View Article] [PubMed]
     [Google Scholar]
  46. Zintgraff J, Fossati S, Pereira CS, Veliz O, Regueira M et al. Distribution of PCV13 and PPSV23 Streptococcus pneumoniae serotypes in Argentinean adults with invasive disease, 2013–2017. Rev Argent Microbiol 2020; 52:189–194 [View Article] [PubMed]
     [Google Scholar]
  47. Lekhuleni C, Ndlangisa K, Gladstone RA, Chochua S, Metcalf BJ et al. Impact of pneumococcal conjugate vaccines on invasive pneumococcal disease-causing lineages among South African children. Nat Commun 2024; 15:8401 [View Article] [PubMed]
     [Google Scholar]
  48. VIEW-hub by IVAC Netherlands; 2024 https://view-hub.org/map/country/nld#vaccine-introduction accessed 11 December 2024
  49. Balsells E, Dagan R, Yildirim I, Gounder PP, Steens A et al. The relative invasive disease potential of Streptococcus pneumoniae among children after PCV introduction: a systematic review and meta-analysis. J Infect 2018; 77:368–378 [View Article] [PubMed]
     [Google Scholar]
  50. Wagenvoort GHJ, Sanders EAM, Vlaminckx BJ, de Melker HE, van der Ende A et al. Sex differences in invasive pneumococcal disease and the impact of pneumococcal conjugate vaccination in the Netherlands, 2004 to 2015. Euro Surveill 2017; 22:30481 [View Article] [PubMed]
     [Google Scholar]
  51. Cremers AJH, Meis JF, Walraven G, Jongh CE van der G, Ferwerda G et al. Effects of 7-valent pneumococcal conjugate 1 vaccine on the severity of adult 2 bacteremic pneumococcal pneumonia. Vaccine 2014; 32:3989–3994 [View Article] [PubMed]
     [Google Scholar]
  52. Hanage WP, Finkelstein JA, Huang SS, Pelton SI, Stevenson AE et al. Evidence that pneumococcal serotype replacement in Massachusetts following conjugate vaccination is now complete. Epidemics 2010; 2:80–84 [View Article] [PubMed]
     [Google Scholar]
  53. Hoge CW, Reichler MR, Dominguez EA, Bremer JC, Mastro TD et al. An epidemic of pneumococcal disease in an overcrowded, inadequately ventilated jail. N Engl J Med 1994; 331:643–648 [View Article] [PubMed]
     [Google Scholar]
  54. Nakano S, Fujisawa T, Ito Y, Chang B, Matsumura Y et al. Streptococcus pneumoniae serotype 12F-CC4846 and invasive pneumococcal disease after introduction of 13-valent pneumococcal conjugate vaccine, Japan, 2015–2017. Emerg Infect Dis 2020; 26:2660–2668 [View Article] [PubMed]
     [Google Scholar]
  55. Schillberg E, Isaac M, Deng X, Peirano G, Wylie JL et al. Outbreak of invasive Streptococcus pneumoniae serotype 12F among a marginalized inner-city population in Winnipeg, Canada, 2009-2011. Clin Infect Dis 2014; 59:651–657 [View Article] [PubMed]
     [Google Scholar]
  56. Teodoro IMM. Pneumococcal invasive disease in adults (2015-2017): epidemiological and molecular characterization of Streptococcus pneumoniae and genomic analysis of emerging clones; 2020 https://repositorio.ul.pt/handle/10451/46374 accessed 8 November 2023
  57. Lekhuleni C. Personal communication
     [Google Scholar]
  58. González-Díaz A, Càmara J, Ercibengoa M, Cercenado E, Larrosa N et al. Emerging non-13-valent pneumococcal conjugate vaccine (PCV13) serotypes causing adult invasive pneumococcal disease in the late-PCV13 period in Spain. Clin Microbiol Infect 2020; 26:753–759 [View Article] [PubMed]
     [Google Scholar]
  59. Gladstone RA, Lo SW et al. GPSC26. Microreact 2019 https://microreact.org/project/gpsGPSC26 accessed 11 December 2024
     [Google Scholar]
  60. Gladstone RA, Lo SW et al. GPSC55. Microreact 2019 https://microreact.org/project/gpsGPSC55 accessed 11 December 2024
     [Google Scholar]
  61. Gladstone RA, Lo SW et al. GPSC32. Microreact 2019 https://microreact.org/project/gpsGPSC32 accessed 11 December 2024
     [Google Scholar]
  62. Vandenbroucke-Grauls CMJE. Antimicrobial resistance in the Netherlands: a natural experiment?. Front Public Health 2014; 2:5 [View Article] [PubMed]
     [Google Scholar]
  63. The Center for Disease Dynamics, Economics & Policy ResistanceMap: antibiotic resistance. ResistanceMap; 2018 https://resistancemap.OneHealthTrust.org/AntibioticResistance.php accessed 2 May 2024
  64. de Greeff C, Kolwijck E, Schoffelen AF. NethMap 2023. Consumption of antimicrobial agents and antimicrobial resistance among medically important bacteria in the Netherlands in 2022 / MARAN 2023. Monitoring of Antimicrobial Resistance and Antibiotic Usage in Animals in the Netherlands in 2022; National Institute for Public Health and the Environment, Bilthoven, The Netherlands; 2023 accessed 10 December 2024
  65. Teixeira R, Kossyvaki V, Galvez P, Méndez C. Pneumococcal serotype evolution and burden in European adults in the last decade: a systematic review. Microorganisms 2023; 11:1376 [View Article] [PubMed]
     [Google Scholar]
/content/journal/mgen/10.1099/mgen.0.001377
Loading
Investigating two decades of Streptococcus pneumoniae bacteraemia in the Gelderland area, the Netherlands, using whole-genome sequencing
M Gen 11, 001377 (2025); https://doi.org/10.1099/mgen.0.001377
/content/journal/mgen/10.1099/mgen.0.001377
/content/journal/mgen/10.1099/mgen.0.001377
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An error occurred
Approval was partially successful, following selected items could not be processed due to error